In addition, higher levels of biomarkers associated with inflammation (LAG-3 and CD8 expression) in baseline tumors enriched for RFS benefit in both treatment arms, similar to trends observed for PFS in patients with advanced melanoma in RELATIVITY-047 (ref. 9). This evidence concerns the gene CD8A and melanoma.